Supernus to Participate in the Wells Fargo Healthcare Conference
31 août 2023 17h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Bethany L. Sensenig Joins Supernus’ Board of Directors
21 août 2023 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2023 Financial Results
08 août 2023 16h17 HE
|
Supernus Pharmaceuticals, Inc.
Qelbree® net product sales growth of 179% and 193% in the second quarter and first six months of 2023, respectively, compared to the same periods in 2022$31.0 million and $56.8 million of net...
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
24 juil. 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 24, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in the Jefferies Healthcare Conference
31 mai 2023 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2023 Financial Results
09 mai 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter...
Supernus to Present at the Bank of America 2023 Health Care Conference
02 mai 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
25 avr. 2023 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Repayment of Convertible Notes
03 avr. 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Two Upcoming Investor Conferences
08 mars 2023 16h05 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...